Cytosorbents Corporation (CTSO) fundamentals score
CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Surgical & Medical Instruments & Apparatus · Healthcare · Listed on NASDAQ
Overall: 4.2 out of 10, Weak long-term fundamentals
- Growth: 3.4/10
- Profitability: 4.3/10
- Financial health: 2.5/10
- Earnings quality: 7.7/10
- Valuation: 4.3/10
Scores are calculated from Cytosorbents Corporation’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10